We have produced a first list of real-world evidence (RWE) outcomes for Alzheimer’s disease across the spectrum, having drawn upon findings from literature and following consultation with some of our partners within the Consortium who are leading experts in their fields in both academia and industry.
In the next stages of our work, we will prioritize outcomes and agree on criteria for meaningful delay in disease progression through synthesizing our findings from systematic reviews, stakeholder surveys, priority setting workshops and on-going collaboration within the Consortium.